NYSE:DHR 21 October 2025 - 15 February 2026

Danaher shares fell 1.2% to $212.58 in after-hours trading Friday, following a session range of $210.80 to $218.48 on 5.3 million shares traded. The drop comes ahead of the Presidents Day market closure, with trading set to resume Tuesday. The stock remains below its 52-week high as traders await next week’s PCE inflation data.

Danaher shares closed up 2.1% at $223.42 Monday, ending a four-day slide and holding steady after hours. The company forecasts 2026 core revenue growth of 3% to 6% and adjusted EPS of $8.35 to $8.50. Investors are watching for signs of renewed lab and pharma spending amid a U.S. government shutdown that has delayed key economic data.

Danaher shares fell 2.2% to $219.49 Thursday after its 2026 profit outlook matched analyst estimates. Fourth-quarter revenue rose 4.5% to $6.8 billion, with adjusted earnings at $2.23 per share. CEO Rainer Blair said China diagnostics revenue declined only slightly in Q4, improving from previous quarters. Investors remain cautious as sector peers warn of continued weakness in academic research spending.

Danaher shares fell 4.8% to $224.54 after its 2026 profit outlook matched analyst expectations. The company beat fourth-quarter profit and revenue estimates, posting $6.8 billion in revenue and $2.23 per share in adjusted earnings. Trading volume more than doubled its 50-day average. Investors focused on the pace of recovery and upcoming results from rival Thermo Fisher.

Danaher shares closed down 0.42% at $235.60 Wednesday, then edged up 0.16% after hours. CEO Rainer Blair will present at the J.P. Morgan Healthcare Conference Jan. 13, with Q4 earnings set for Jan. 28. Evercore ISI and TD Cowen raised price targets to $250 and $270, respectively. The stock traded between $233.26 and $238.00, with 2.7 million shares changing hands.

Danaher shares traded at $227–$229 Thursday, rebounding over 30% from April’s low but still 11–12% below the 52-week high. The company faces board governance probes as Morgan Stanley upgrades the stock and new institutional buyers emerge. Danaher forecasts mid-single-digit revenue growth and margin expansion for 2026. Q3 2025 saw 3% core revenue growth and $2 billion in share buybacks.

Danaher traded near $225 per share on December 1, 2025, down about 1%–2% year-to-date and roughly 12% below its 52-week high. Market cap stands at $159–160 billion. Halper Sadeh LLC launched a shareholder-rights investigation into Danaher officers and directors on November 28, following similar probes by Rosen Law Firm in October. No lawsuits or regulatory actions have been filed.